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Study Need and Importance: Upper tract urothelial
carcinoma (UTUC) is a rare malignancy, representing only 5%e10% of urothelial carcinomas. Despite
its incidence, this malignancy is typically diagnosed
at a high stage with 30% of patients presenting with
lymph node metastasis. Utility of lymph node
dissection (LND) during nephroureterectomy on
oncologic outcomes in UTUC is not well defined. In
this study, we sought to evaluate the impact of LND
on prognosis, survival and oncologic outcomes in a
multi-institutional cohort of patients with UTUC.
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Full-length article available at auajournals.org/10.1097/JU.0000000000002690.
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What We Found: In our study, we found that lymphadenectomy in patients undergoing robotic
nephroureterectomy with lymph node positive disease does not improve 2-year overall (p <0.001),
cancer-specific (p <0.001) or recurrence-free (p
<0.001) survival outcomes. However, LND can
provide important prognostic information for
further characterization, staging and treatment of
tumors before or after surgical resection. Furthermore, we found that large (OR 1.14, p[0.001) and
high-grade (OR 11.74, p[0.015) tumors were more
likely to have lymph node metastasis on diagnosis.
Lastly, we observed that patients with clinical node
negative disease may benefit from extended node
dissection. Patients with clinical node negative disease who had dissection of 10 or more lymph nodes
showed improved 2-year recurrence-free survival
(p[0.043) compared to those with node negative
disease and fewer than 10 nodes dissected, and patients with no node dissection (see Figure).
Limitations: Our multi-institutional study is limited
by lack of a standardized dissection template and
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Figure. Kaplan-Meier analysis comparing patients who did not
undergo LND (pNx), and patients who underwent LND with
negative (pN0) and positive (pND) nodes for recurrence-free
survival outcomes.

central pathological review, which may limit the
accuracy of lymph node yield. However, surgeries
were performed by experienced urologists at centers
of excellence.
Interpretation for Patient Care: Overall, our data
point to refinement of selection criteria for LND in
UTUC. Our study shows that in patients with large
tumors and high-grade disease, LND may be deferred
due to high likelihood of lymph node metastasis.
Additionally, in patients with clinical node-negative
disease, extended LND may provide a significant
survival benefit.
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ABBREVIATIONS
and Acronyms
BMI [ body mass index
CSS [ cancer-specific survival

UN
CO

RR

Purpose: We sought to evaluate outcomes of lymph node dissection (LND) in
patients with upper tract urothelial carcinoma.
Materials and Methods: We performed a multicenter retrospective analysis
utilizing the ROBUUST (for RObotic surgery for Upper Tract Urothelial Cancer
Study) registry for patients who did not undergo LND (pNx), LND with negative
lymph nodes (pN0) and LND with positive nodes (pND). Primary and secondary
outcomes were overall survival (OS) and recurrence-free survival (RFS). Multivariable analyses evaluated predictors of outcomes and pathological node positivity. Kaplan-Meier analyses (KMAs) compared survival outcomes.
Results: A total of 877 patients were analyzed (LND performed in 358 [40.8%]/pND
in 73 [8.3%]). Median nodes obtained were 10.2 for pND and 9.8 for pN0. Multivariable analyses noted increasing age (OR 1.1, p <0.001), pND (OR 3.1, p <0.001)
and pathological stage pTis/3/4 (OR 3.4, p <0.001) as predictors for all-cause mortality. Clinical high-grade tumors (OR 11.74, p[0.015) and increasing tumor size
(OR 1.14, p[0.001) were predictive for lymph node positivity. KMAs for pNx, pN0

EBL [ estimated blood loss
KMA [ Kaplan-Meier analysis
LN [ lymph node
LND [ lymph node dissection
MVA [ multivariable analysis
OS [ overall survival
pNþ [ patients who underwent
lymph node dissection with positive nodes
pN0 [ patients who underwent
lymph node dissection with
negative nodes
pNx [ patients who did not undergo lymph node dissection
RFS [ recurrence-free survival
UC [ urothelial carcinoma
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UTUC [ upper tract urothelial
carcinoma
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and pND demonstrated 2-year OS of 80%, 86% and 42% (p <0.001) and 2-year RFS of 53%, 61% and 35%
(p <0.001), respectively. KMAs comparing pNx, pN0 10 nodes and pN0 <10 nodes showed no significant difference in 2-year OS (82% vs 85% vs 84%, p[0.6) but elicited significantly higher 2-year RFS in the
pN0 10 group (60% vs 74% vs 54%, p[0.043).
Conclusions: LND during nephroureterectomy in patients with positive lymph nodes provides prognostic
data, but is not associated with improved OS. LND yields 10 in patients with clinical node negative disease
were associated with improved RFS. In high-grade and large tumors, lymphadenectomy should be considered.

F

Key Words: lymph node excision, nephrectomy, nephroureterectomy
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patient age, gender and body mass index (BMI, kg/m2).
Clinical disease features included tumor size (cm), grade and
node status at time of diagnosis, and receipt of neoadjuvant
or adjuvant chemotherapy. Perioperative parameters included estimated blood loss (EBL, ml), and intraoperative
and 30-day complications (Clavien).13 Pathological data
included tumor size and stage,14 focality, grade, presence of
lymphovascular invasion, LNs removed and margin status.
Survival outcome data included recurrence, overall survival
(OS) and cancer-specific survival (CSS).

D

Statistical Analysis
The cohort was divided into patients who did not undergo
LND (pNx), patients who underwent LND with negative
LNs (pN0) and patients who underwent LND with positive nodes (pND). Primary outcome was OS. Secondary
outcomes were CSS and recurrence-free survival (RFS).
Descriptive analyses were conducted utilizing Kruskall
Wallis Test (nonparametric 1-way ANOVA) and Mann
Whitney U tests (see supplementary Table, https://www.
jurology.com) for categorical variables and ANOVA for
continuous variables. Multivariable analyses (MVAs)
using Cox regression was conducted for OS, CSS and RFS
utilizing clinically significant variables and known risk
factors found on descriptive analyses. Logistic regression
MVAs were conducted for predictors of pathological node
positivity. Kaplan-Meier analyses (KMAs) evaluated survival outcomes based on nodal status. SPSSÒ v.27 (IBMÒ,
Armonk, New York) were utilized for statistical analyses,
with p <0.05 considered significant.

METHODS
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UPPER tract urothelial carcinoma (UTUC) is a rare
malignancy, representing only 5%e10% of urothelial carcinomas (UCs).1 Despite low incidence,
UTUC is typically diagnosed at high stage and
carries a poorer prognosis than UC of the bladder.2
Thirty percent of patients with UTUC present with
lymph node (LN) metastasis, an independent risk
factor for poor oncologic outcomes.3,4
Benefits of LN dissection (LND) in UC of the
bladder on oncologic outcomes are well-established.5,6 Although bladder UC and UTUC share
similar characteristics, it is unclear whether oncologic benefits are present for LND in UTUC.7,8
Nephroureterectomy with bladder cuff excision is
the standard treatment for UTUC, but studies
assessing value of LND in nephroureterectomy on
oncologic outcomes have been more controversial.1,8,9 Recent European Association of Urology
guidelines recommend LND for optimal tumor
staging in clinical circumstances suspicious for LN
positivity, but impact of LND in circumstances of
clinical node negativity are unclear.10,11 We sought
to evaluate impact of LND on prognosis, survival
and oncologic outcomes in a contemporary cohort of
patients with UTUC.

Patient Populations/Study Design

We performed a multicenter retrospective analysis utilizing the ROBUUST registry (for RObotic surgery for Upper
Tract Urothelial Cancer Study) of UTUC patients undergoing nephroureterectomy from 2006e2019. Our evaluation and operative protocols have been recently described.12
Institutional Review Board approval was obtained at all
centers (IRB No. 161197). Patients presenting with signs
and symptoms for UTUC underwent radiological staging
and tissue confirmation via ureteroscopic or percutaneous
biopsy. Decision to proceed with LND was based on presence of clinical lymphadenopathy or risk for LN metastasis.
Anatomical template of LND was at the treating surgeon’s
discretion. We excluded patients who presented with metastatic disease and variant histologies.

Data Collected
This is a retrospectively collected data set by data set managers at participating institutions. Demographic, clinical and
disease features were recorded. Demographics included

RESULTS
A total of 877 patients were analyzed (mean followup 13.4 months). LND was performed in 358
(40.8%), with pND in 73 (8.3%). Mean number of
nodes removed for pN0 and pND was 9.8 and 10.2,
respectively. Table 1 presents demographics and
disease characteristics comparing pNx, pN0 and
pND patients. Compared to pN0/pNx patients,
pND patients had larger mean clinical tumor size
(pND 4.1 vs pN0 3.6 vs pNx 3.3 cm, p[0.01),
greater proportion presenting with clinical lymphadenopathy (pND 23.3% vs pN0 4.2% vs pNx 4.3%,
p <0.001) and high-stage (Tis/III/IV) tumors (pND
98.6% vs pN0 82.8% vs pNx 80.2%, p <0.001). Patients with pND had greater EBL compared to both
pN0/pNx patients (pND 241 vs pN0 155 vs pNx 143
ml, p <0.001). Patients had no differences in

Copyright © 2022 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
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respectively, with pND patients demonstrating
significantly worse 2-year survival (p <0.001). KMA
of CSS is shown in Figure 1, B. The 2-year CSS for
pNx, pN0 and pND groups was noted to be 90%, 91%
and 45%, respectively, with pND patients demonstrating significantly worse 2-year CSS (p <0.001).
Figure 1, C demonstrates KMA of RFS. The 2-year
RFS for pNx, pN0 and pND groups was noted to be
53%, 61% and 35%, respectively, with pND patients
demonstrating significantly increased 2-year recurrence (p <0.001). Figure 2 demonstrates KMA of
comparison of OS, CSS and RFS based on nodal count
obtained in the nonmetastatic group, comparing
pNx (0 LN), pN0 (10 nodes) and pN0 (<10 nodes).
We noted no significant differences between groups
with respect to 2-year OS (pNx 82% vs pN0 10
nodes 85% and pN0 <10 nodes 84% [p[0.6],
Figure 2, A) and 2-year CSS (pNx 89% vs pN0 10
nodes 90% and pN0 <10 nodes 93% [p[0.9],
Figure 2, B). However, we noted significantly higher

Table 1. Demographics and clinical disease characteristics
LNx

LNþ

519
285
13.7 (16.7) 15.6 (18)
71.3 (10.1) 69.1 (9.6)

73
10.9 (13.6)
71.1 (9.8)

232
287
27.3
3.3

28
45
26.5
4.1

(65.4) 95 (33.3)
(55.3) 190 (66.7)
(5.1) 27.7 (5.8)
(1.9)
3.6 (1.9)

p Value

0.01
0.007

(38.4)
(61.6)
(4.3)
(2.1)

0.2
0.01

(6.6)
(7.7)
(4.8)
(0.0)

5 (6.8)
22 (30.1)

30 (10.5)
23 (8.2)
9 (3.2)
9.8 (9.5)

13
26
11
10.2

103 (19.8) 49 (17.2)
416 (80.2) 236 (82.8)

1
72

370 (71.3) 213 (74.7)
149 (28.7) 72 (25.3)
100 (19.3) 35 (12.3)

16
57
53

0.2
0.5

(17.8)
0.003
(36.6) <0.001
(15.3) <0.001
(9.5) <0.001
<0.001
(1.4)
(98.6)
<0.001
(21.9)
(78.1)
(72.6) <0.001

PR

34
40
25
0

7 (2.5)
59 (20.8)

D

17 (3.3)
125 (24.1)

OO

159 (30.6) 53 (18.6) 14 (19.2) <0.001
22 (4.3) 12 (4.2) 17 (23.3) <0.001
143 (166) 155 (134) 241 (333) <0.001

Table 2. Multivariable analyses
Variable

HR (95% CI)

TE

No. pts
Mean mos followup (SD)
Mean yrs age (SD)
No. sex (%):
Female
Male
Mean kg/m2 BMI (SD)
Mean cm clinical tumor
size (SD)
No. multifocal (%)
No. lymphadenopathy (%)
Mean ml EBL (SD)
No. complications (%):
Intraop
Postop
No. chemotherapy (%):
Neoadjuvant
Adjuvant
No. pos margin (%)
Mean No. nodes removed (SD)
No. tumor grade (%):
Low (I, II)
High (Ca in situ, III, IV)
No. pathological stage (%):
Low (I, II)
High (Tis, III, IV)
No. lymphovascular
invasion (%)

LN0

F

Variable

3

*p Value generated using Kruskall-Wallis Test.
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intraoperative (p[0.2) and postoperative complications (p[0.5). Compared to pN0 and pNx patients,
pND patients had a greater proportion of positive
surgical margins (pND 15.3% vs pN0 3.2% vs pNx
4.8%, p <0.001), high-grade tumors (pND 78.1% vs
pN0 25.3% vs pNx 28.7%, p <0.001) and lymphovascular invasion (pND 72.6% vs pN0 12.3% vs pNx
19.3%, p <0.001). Patients with pND were more
likely to receive neoadjuvant therapy (p[0.003).
Table 2 demonstrates MVAs for outcomes and LN
positivity. Cox regression for all-cause mortality
noted increasing age (HR 1.06, p <0.001), pND (HR
2.77, p <0.001) and pathological stage pTis/3/4 (HR
3.89, p <0.001) as risk factors associated with
worsened all-cause mortality. Cox regression for
cancer-specific mortality noted male sex (HR 2.38,
p[0.008), pND (HR 2.74, p[0.006) and pathological stage pTis/3/4 (HR 4.18, p[0.003) as predictive
for cancer-specific mortality. Cox regression for
recurrence found multifocality (HR 1.59, p[0.002),
pND (HR 1.8, p[0.005) and lymphovascular invasion (HR 1.23, p[0.033) to be associated with
increased risk for recurrence. Logistic regression
evaluating predictors for pND disease found high
clinical tumor grade (OR 11.74, p[0.015) and
increasing tumor size (OR 1.14, p[0.001) to be
associated with LN positivity (Table 2).
Figure 1, Ademonstrates KMA of OS stratified
by nodal status. The 2-year OS for pNx, pN0 and
pND groups was noted to be 80%, 86% and 42%

Factors associated with all-cause mortality
Increasing age (continuous)
1.06 (1.03e1.09)
Sex (male vs female)
1.13 (0.73e1.76)
Increasing BMI (continuous)
1.03 (0.99e1.07)
Multifocal vs unifocal
1.33 (0.72e2.44)
High grade vs low grade
1.44 (0.61e3.39)
LN status (LNx referent):
LN0
1.60 (0.93e2.76)
LN1
2.77 (1.59e4.84)
Stage (Tis, III, IV vs 0, I, II)
3.89 (2.29e6.63)
Lymphovascular invasion (yes vs no)
1.34 (0.95e1.90)
Increasing tumor size (continuous)
0.94 (0.85e1.05)
Factors associated with cancer-speciﬁc mortality
Increasing age (continuous)
1.01 (0.98e1.05)
Sex (male vs female)
2.38 (1.26e4.51)
Multifocal vs unifocal
1.67 (0.72e3.85)
High grade vs low grade
1.66 (0.21e13.29)
LN status (LNx referent):
LN0
1.58 (0.75e3.33)
LN1
2.74 (1.34e5.61)
Stage (Tis, III, IV vs 0, I, II)
4.18 (1.61e10.85)
Increasing tumor size (continuous)
1.04 (0.83e1.23)

p Value
<0.001
0.6
0.18
0.4
0.4
0.09
<0.001
<0.001
0.09
0.3
0.4
0.008
0.2
0.6
0.2
0.006
0.003
0.9

Factors associated with recurrence
Increasing age (continuous)
1.01 (0.99e1.03)
Sex (male vs female)
1.08 (0.82e1.40)
Increasing BMI (continuous)
1.02 (0.99e1.04)
Multifocal vs unifocal
1.59 (1.19e2.13)
High grade vs low grade
1.03 (0.71e1.48)
LN status (LNx referent):
LN0
1.01 (0.75e1.35)
LN1
1.80 (1.20e2.71)
Stage (Tis, III, IV vs 0, I, II)
1.07 (0.80e1.45)
Increasing tumor size (continuous)
0.99 (0.93e1.05)
Lymphovascular invasion (yes vs no)
1.23 (1.02e1.78)

0.9
0.005
0.6
0.6
0.033

Factors associated with LN positivity
Increasing age (continuous)
1.02 (0.99e1.04)
Sex (male vs female)
1.16 (0.70e1.93)
Increasing BMI (continuous)
0.98 (0.93e1.04)
Multifocal vs unifocal
0.83 (0.44e1.57)
High grade vs low grade
11.74 (1.62e85.11)
Increasing tumor size (continuous)
1.14 (1.05e1.24)

0.3
0.6
0.5
0.6
0.015
0.001

Copyright © 2022 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
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Figure 1. KMAs comparing pNx, pN0 and pND groups for survival outcomes. A, OS. B, CSS. C, RFS.
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Figure 2. KMAs comparing pNx, pN0 >10, pN0 10 for survival outcomes. A, OS. B, CSS. C, RFS.
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2-year RFS in pN0 10 nodes compared to pN0 <10
nodes and pNx (noted to be 74%, 54% and 60%,
respectively, p[0.043; Figure 2, C).
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We report findings of a large multicenter retrospective cohort study examining impact of LND in the
setting of robotic nephroureterectomy. Our findings
suggest that while LND is not associated with
cancer-specific and OS benefit in the setting of
pathological LN negative disease, it may provide
important prognostic information, and when 10 or
more LNs are obtained, improved RFS can be
observed. Furthermore, patients at higher risk for
LN-positive disease, namely high tumor grade and
large tumor size of 4.5 cm, should be considered for
LND. While our latter finding is novel and requires
confirmatory investigation, it calls for promulgation
of selection criteria and technical guidelines for LND
in the setting of localized UTUC to refine staging,
prognostication and oncologic outcomes.
The prognostic benefits of LND during radical
nephroureterectomy are well established. Secin
et al retrospectively analyzed 252 cN0/cND patients
undergoing radical nephroureterectomy and
demonstrated a 11% pND rate with significantly
decreased 5-year CSS of pND patients compared to
pN0 and pNx patients (pND 0% vs pN0 56% vs pNx
73%, p <0.0005), though no difference between pNx
and pN0 patients (p[0.40).15 Importantly, 60% of
patients with pND disease had suspicious clinically
positive imaging prior to surgery, as well as 23% of
the total cohort. Similar results emphasizing survival advantage in pN0/pNx patients relative to
pND patients have been reproduced by other
multicenter national database studies of cN0/cND
cohorts.16e20 Similarly, our findings noted that
when compared to pND, patients with pN0/pNx
experienced better OS (pND 42% vs pN0 86%,
pNx 80%, p <0.001) and RFS (pND 35% vs pN0
61%, pNx 53%, p <0.001).
Therapeutic benefits of LND are more controversial. In a multicenter retrospective analysis of
1,130 patients undergoing nephroureterectomy
(36.5% pN0, 12.4% pND and 51.1% pNx; median
followup 45 months), Roscigno et al reported
improved 5-year CSS in pN0 disease compared to
pNx (77% vs 69%, p[0.024).17 In contrast, Ikeda
et al analyzed 404 patients (40 [10%] pND, number
of nodes removed 8; 182 [46%] pN0, number of nodes
removed 6; and 177 [44%] pNx, with median followup 43 months) and found that patients with
pT2 disease received no benefit, but those with
pT3 or more advanced staging had improved OS
(HR[2.07, p[0.002) and CSS (HR[2.66, p[0.001)
with LND.20 Lughezzani et al analyzed 2,824 cN0

F

DISCUSSION

(median number of nodes not reported)/cND patients undergoing nephroureterectomy and found
no significant difference in 5-year CSS between pNx
vs pN0 (78 vs 81 months, p[0.09).18 In our analysis
of pN0 (median number nodes removed 9.8) and
pND (median number nodes removed 10.2) patients, we found no benefits in OS, CSS and RFS for
patients with pN0 compared to pNx at 2-year followup (OS, pN0 86% vs pNx 80%, p[0.09; CSS, pN0
91% vs pNx 90%, p[0.55; RFS pN0 61% vs pNx
53%, p[0.06). Taken together, these findings suggest that primary benefit in this group is likely
prognostic, not therapeutic, and thus LND may be
reserved in patients for whom such information is
meaningful.
Nonetheless we noted improved RFS in patients
who underwent LND and whose nodal count was
10 compared to pN0 patients with <10 nodes
dissected and pNx patients (74% vs 54% vs 60%,
p[0.043). Currently there is no consensus on the
optimal standard template for LND in UTUC.
Rather, the number of LNs removed can be used as
a surrogate to determine the extent and quality of
the LND procedure. A meta-analysis conducted by
Choo et al identified improved ACM in pN0 UTUC
patients with a higher number of nodes removed
(HR 0.86, p <0.01).21 Roscigno et al retrospectively
analyzed 552 patients with UTUC who underwent
nephroureterectomy with LAN, demonstrating that
patients with LN yield 8 showed improved RFS
(HR 0.49, p <0.01) and CSS (HR 0.42, p <0.01).22
Our findings, while not showing improvement in OS
and CSS for pN0 patients with 10 LNs, showed
significantly improved RFS. Taken together, these
data call for further investigation into impact of LN
yield and standardization of LND templates to
optimize outcomes in cN0 UTUC.
A potential concern for performance of LND at
time of nephroureterectomy is increased risk of surgical complications. A meta-analysis of 18,584 patients by Chan et al noted that LND did not increase
the risk of postoperative complications (RR 1.06,
p[0.07).23 Pearce et al analyzed 16,619 patients who
underwent nephroureterectomy (11,682 open/2,638
laparoscopic/2,286 robotic) between 2009 to 2012
and noted that while LND increases the risk of
intraoperative complications (OR 1.3, p[0.049), performance of robotic nephroureterectomy was associated with decreased risk of overall complications
compared to open approach (OR 0.55, p[0.001).24 In
our cohort, LND was not associated with significant
differences in intraoperative (p[0.2) or postoperative
(p[0.5) complications, suggesting that lymphadenectomy in the setting of a robotic approach did not
increase risk of adverse events and may be considered an important portion of the procedure that provides clear prognostic benefit in select patients.
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improved disease-free survival (HR[0.45, p <0.001)
and metastasis-free survival (HR[0.48, p[0.0007)
with adjuvant therapy at 30-month followup.27 In
a meta-analysis conducted by Leow et al, neoadjuvant therapy had a significant improvement
in OS (HR[0.44, p <0.001) and CSS (HR[0.38,
p <0.001) compared to nephroureterectomy alone.28
As a paradigm shift towards utilization of adjuvant
and neoadjuvant therapy occurs, identification of LN
metastasis is critical. While requiring confirmation,
our findings suggest optimization of selection for
lymphadenectomy.
There are important limitations to note. The
retrospective study design is subject to inherent
biases. Our series lacks a standardized
dissection template and lack of central pathology
review which may limit accuracy of LN yield.
Nonetheless, surgeries were performed by experienced urological surgeons at centers of excellence
according to previously reported protocols.12 Patients with high tumor stage or grade were more
likely to receive LND, which may bias our results.
Additionally, a small number of patients were ultimately pND which can impart selection bias.
Despite these limitations, our study is unique in its
delineation of selection criteria for lymphadenectomy and demonstration of potential survival
benefit in patients with LN yields 10. While findings may be hypothesis-generating and further
investigation is requisite, their applicability is
bolstered by the large, international cohort of
diverse patients.
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Selection criteria for performance of lymphadenectomy at time of nephroureterectomy beyond
clinical principle (lymphadenopathy on preoperative
images or intraoperative examination) and in
setting of clinically negative LNs are unclear, and
little has been reported with respect to predictors of
LN positivity. In our series, we identified high
tumor grade (OR[11.74, p[0.015) as well as
increasing tumor size (OR[1.14, p[0.001) as independent predictors of pND disease. Inokuchi et al
performed a multicenter analysis of 2,037 patients
with UTUC in which LND was performed 1,046
(51.4%), of whom 223 patients (10.9%) were pND.
In a MVA for predictors of pND, advanced age (>70
years, OR[1.68, p[0.007), clinical T3D disease
(OR[2.34, p <0.001) and clinically positive LNs
(OR[12.6, p <0.001) on imaging were predictive for
pathological LN invasion.25 Their regression model
did not include clinical tumor size or grade, but age,
hydronephrosis and tumor location were not noted
to be predictive for LN positivity. Our findings build
on those of Inokuchi et al and suggest that in patients with high-grade disease and large tumors
LND may be considered for risk stratification to
detect pND disease. Furthermore, we observed only
1 case of low-grade pND disease, in a patient with
tumor size of 6 cm, similar to Secin et al, who
identified no instances of low-grade node-positive
disease in a series of 252 patients.15 Taken
together, these findings suggest that LND may be
safely omitted in patients with small and low-grade
tumors.
Obtaining prognostic information regarding LN
status has assumed increasing importance due to
emerging data supporting utilization of adjuvant
and neoadjuvant therapy. Utilizing the National
Cancer Database, Pelcovits et al analyzed 794
patients with pND UTUC and found that adjuvant therapy had significant improvement in OS
(p <0.001).26 Recent publication by Birtle et al of the
POUT clinical trial supports investigation of LN
disease status at time of nephroureterectomy.27
POUT randomized 261 patients with advanced
localized or LN-invasive nonmetastatic UTUC to
adjuvant chemotherapy or surveillance, and found

7

CONCLUSIONS
Lymphadenectomy in patients undergoing robotic
nephroureterectomy is not associated with
increased complications, can provide important
prognostic information, and should be considered in
patients with high-grade disease and large tumors
even in the setting of clinical node-negative disease.
Furthermore, LN yields 10 in cN0 patients may be
associated with improved RFS. Our data point to
refinement of selection criteria and outcomes for
lymphadenectomy in nephroureterectomy patients.
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